AustralianSuper’s Alnylam Pharmaceuticals ALNY Stock Holding History

AustralianSuper’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.45M	Hold	4,803	–	–	0.01%	250
2026 Q1	$1.59M	Hold	4,803	–	–	0.01%	246
2025 Q4	$1.91M	Sell	4,803 -939	-16%	-$416K	0.01%	228
2025 Q3	$2.62M	Buy	5,742 +1,524	+36%	+$621K	0.01%	225
2025 Q2	$1.38M	Hold	4,218	–	–	0.01%	234
2025 Q1	$1.14M	Hold	4,218	–	–	0.01%	200
2024 Q4	$993K	Buy	4,218 +573	+16%	+$151K	﹤0.01%	200
2024 Q3	$1M	Buy	+3,645	New	+$949K	0.01%	211

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AustralianSuper's ALNY Position: Q2 2026 in Review

AustralianSuper held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 4,803 shares worth $1.45M. The position accounts for 0.01% of the portfolio, ranked #250.

AustralianSuper first reported a position in ALNY in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.62M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

AustralianSuper held 4,803 shares of Alnylam Pharmaceuticals worth $1.45M as of Q2 2026.
AustralianSuper left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up 0.01% of AustralianSuper's portfolio in Q2 2026, its #250 holding.
AustralianSuper first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
AustralianSuper's Alnylam Pharmaceuticals position peaked at $2.62M in Q3 2025.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on AustralianSuper's 13F filing for Q2 2026, filed 12 Aug 2026.